3 November 2026
Australia has taken an important step towards improving access to reproductive healthcare. The Therapeutic Goods Administration (TGA) has approved the use of medical abortion medication up to 10 weeks of pregnancy, extending the previous limit of nine weeks.
Announced on 21 October 2026, the decision also approves the same medication for managing missed miscarriage, providing another recognised treatment option for people experiencing early pregnancy loss.
While an additional seven days may seem like a modest change, it can make a meaningful difference for people navigating the practical, financial and personal complexities of accessing abortion care.
What has changed?
The TGA has expanded the approved uses of MS-2 Step, a medication containing mifepristone and misoprostol.
These medications work together to end an early pregnancy. Mifepristone blocks the action of progesterone, a hormone needed to maintain pregnancy, while misoprostol causes the uterus to contract and expel the pregnancy tissue.
Previously, MS-2 Step was approved for medical abortion up to 63 days, or nine weeks, of pregnancy. The new approval extends this period to 70 days, or 10 weeks. Pregnancy duration for medical abortion is generally calculated from the first day of the last menstrual period, with further assessment where clinically necessary.
The decision follows a review of clinical research, international evidence and established medical guidelines. It also brings Australia's approved use of the medication into line with recommendations from the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG).
Importantly, 10 weeks is the approved limit for this particular medication regimen, not the legal limit for abortion in Australia. Abortion remains available beyond 10 weeks through other clinical pathways, subject to applicable laws and individual circumstances.
Why does an additional week matter?
Accessing an abortion is not always as straightforward as arranging a medical appointment.
For some people, the process involves finding a healthcare professional who provides abortion services, organising time away from work, managing childcare responsibilities, travelling considerable distances or finding the money to pay for treatment. These difficulties can be especially significant for people living in regional and remote communities, where local services may be limited.
Others may need to navigate concerns about privacy, unsupportive relationships or reproductive coercion. Reproductive coercion occurs when another person interferes with someone's ability to make decisions about contraception, pregnancy or abortion.
These circumstances can create delays that have little to do with a person's readiness to make a decision.
Under the previous approval, someone who passed nine weeks of pregnancy might have needed to pursue a different abortion method, even when medical abortion would otherwise have been clinically appropriate.
Extending the approved timeframe gives more people the opportunity to access their preferred method of care. It can also reduce the pressure created by service delays, particularly for those who have fewer healthcare options.
Is medical abortion safe and effective at 10 weeks?
The TGA's decision was supported by substantial clinical evidence demonstrating that mifepristone and misoprostol remain safe and effective between nine and 10 weeks of pregnancy.
In one large study reviewed by the regulator, successful medical abortion occurred in:
93.5% of pregnancies between 57 and 63 days.
92.8% of pregnancies between 64 and 70 days.
These results demonstrate comparable effectiveness across the two periods. The TGA also identified no new safety concerns associated with extending the approved treatment window.
As with any medical treatment, individual assessment remains important. Medical abortion commonly involves cramping and bleeding, and some people require additional medication or a procedure to complete treatment.
Your prescriber should explain what to expect, how to manage pain, what follow-up care is required and when to seek urgent medical assistance.
The expanded approval does not remove the need for appropriate clinical care. It provides an additional evidence-based option for people who are between nine and 10 weeks pregnant.
More options for people experiencing miscarriage
Alongside the abortion extension, the TGA has approved MS-2 Step for the medical management of missed miscarriage up to 70 days of gestation.
A missed miscarriage occurs when a pregnancy has stopped developing, but the pregnancy tissue remains in the uterus. For this newly approved use, gestational age is determined by ultrasound rather than the date of the last menstrual period.
Although mifepristone and misoprostol have previously been used in miscarriage management, including in hospital settings, MS-2 Step did not have a specific Australian regulatory approval for missed miscarriage.
Some clinicians were already prescribing the medications outside their formally approved indications, known as off-label prescribing. However, access through community-based services has been more limited.
The new approval provides clearer prescribing guidance and may also make it easier to access this care through general practice.
People experiencing missed miscarriage may have several management options, including waiting for the pregnancy tissue to pass naturally, taking medication or undergoing a surgical procedure. The most appropriate approach depends on medical circumstances and individual preferences.
Greater access to these options matters because people should be able to participate meaningfully in decisions about their care, including during pregnancy loss.
An important limitation: Affordability has not yet caught up
While the TGA has approved these expanded uses, the Pharmaceutical Benefits Scheme (PBS) has not yet extended its subsidy to cover them.
As at 3 November 2026, PBS subsidy for MS-2 Step remains limited to medical abortion up to 63 days of pregnancy. This means people seeking medical abortion between 64 and 70 days, or using MS-2 Step for missed miscarriage, may face considerably higher medication costs.
The Pharmaceutical Benefits Advisory Committee (PBAC) recommended extending PBS coverage for medical abortion to 70 days at its July 2026 meeting. It is also scheduled to consider the missed miscarriage indication in November 2026.
However, a recommendation does not automatically result in an immediate subsidy change.
A medication can be approved, clinically appropriate and legally available, yet remain financially inaccessible to some of the people who need it.
This distinction is particularly important in reproductive healthcare, where costs can include much more than the medication itself. Consultations, diagnostic tests, travel, accommodation and time away from paid employment can all influence whether someone can access care.
For this regulatory change to deliver its full benefit, affordability and service availability must improve alongside clinical eligibility.
What does this mean for people seeking abortion care?
People considering an early medical abortion can now discuss the expanded 10-week approval with an appropriately qualified healthcare professional.
Depending on individual circumstances and service availability, medical abortion may be accessible through general practice, specialist reproductive healthcare services or telehealth.
However, not every provider will immediately offer care under the expanded approval. Some services may continue to advertise their previous nine-week limit while reviewing their clinical arrangements.
It is worth contacting a provider directly to confirm their current gestational limits, appointment availability, eligibility requirements and costs.
People who are more than 10 weeks pregnant should also know that other abortion services remain available. The appropriate options depend on pregnancy duration, location, applicable laws and individual clinical circumstances.
Reproductive choice requires more than regulatory approval
The TGA's decision is a positive development in Australian reproductive healthcare. It reflects established clinical evidence, expands treatment options and acknowledges the practical realities of accessing time-sensitive medical care.
But meaningful reproductive autonomy involves more than increasing the number of days a medication can be prescribed. It requires affordable healthcare, accurate information, timely appointments, privacy, respectful treatment and the ability to make decisions free from coercion or unnecessary interference.
It also requires recognising that people approach abortion differently.
Some people are certain about their decision. Others want time to consider their circumstances. Some welcome emotional support, while others neither want nor need counselling. There is no single emotional response to abortion, and no requirement for someone to experience distress for their decision to deserve care and respect.
At Progressive Therapeutic Counselling, abortion is understood as healthcare. When counselling is wanted, it should offer space for reflection, emotional support and self-determination, without judgement or pressure towards a particular outcome.
The same principles apply to experiences of reproductive coercion. Understanding how power, control and relationships influence reproductive decisions is an important part of supporting genuine autonomy.
Australia's expanded medical abortion approval is a welcome change. Its longer-term significance will depend on ensuring that greater clinical choice becomes greater practical choice, particularly for people who have historically faced the greatest barriers to care.
Where to get information and support
1800 My Options (Victoria)
A free, confidential service providing information about contraception, abortion, pregnancy options and sexual health services throughout Victoria.
Phone: 1800 696 784, Monday to Friday, 9 am to 5 pm (excluding public holidays).
Website: 1800myoptions.org.au
MSI Australia (National)
Provides information about medical and surgical abortion services, including telehealth where available and clinically appropriate.
National Contact Centre: 1300 003 707
1800RESPECT (National)
A free, confidential, 24-hour counselling and support service for people experiencing domestic, family or sexual violence, including reproductive coercion.
Phone: 1800 737 732, available 24 hours a day, seven days a week.
Website: 1800respect.org.au
Progressive Therapeutic Counselling
Provides abortion-affirming therapeutic support, including counselling relating to reproductive decisions, reproductive coercion and experiences of abortion.
Website: progressivetherapeutic.com.au
Sources and further reading
Therapeutic Goods Administration (21 October 2026)
Therapeutic Goods Administration (3 November 2026)
MS-2 Step Composite Pack: Australian Public Assessment Report (AusPAR)
Royal Australian and New Zealand College of Obstetricians and Gynaecologists (21 October 2026)
TGA Decision Expands Choice for Abortion and Miscarriage Care
Australian College of Nurse Practitioners (30 October 2026)
Pharmaceutical Benefits Scheme (November 2026)
This article provides general health information and is not a substitute for individual medical advice. Medication eligibility, PBS subsidies and service availability may change.